Clinical trial · Observational
Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer
NCT05495776CI-TRIAL-00061659MSIRus22recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective multicenter registry study to assess the frequency of Lynch syndrome among patients with colorectal cancer in Russia
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Hereditary Colorectal Cancer | — | UNRESOLVED | — |
| Lynch Syndrome | — | UNRESOLVED | — |
| MSI | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with colorectal cancer
- description
- Patients with colon adenocarcinoma who have not previously received antitumor treatment (chemo/radiation therapy) for a currently detected tumor
Primary outcomes (1)
- measure
- Frequency of microsatellite instability and Lynch syndrome
- timeFrame
- up to 5 years
- description
- To assess the frequency of microsatellite instability and Lynch syndrome in the population of patients with colorectal cancer in the Russian Federation.
Secondary outcomes (5)
- measure
- Frequency of occurrence of microsatellite instability/deficiency
- timeFrame
- up to 5 years
- description
- Assessment of the frequency of occurrence of microsatellite instability/deficiency in the repair system of unpaired bases in second tumors in patients with colorectal cancer of various stages.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of written informed consent; * Patients with histologically verified colon adenocarcinoma or patients with histologically verified synchronous neoplasms who have not previously received treatment for a second tumor; * Age ≥ 18 years; * Absence of antitumor treatment for a real tumor (it is allowed to include patients who have a history of antitumor treatment for other malignant tumors, if the period after treatment is more than 12 months). * The ability of the patient, according to the Researcher, to fulfill the requirements of the Protocol; Exclusion Criteria: \- Patients receiving chemotherapy or radiotherapy for colon cancer at the time of screening
References
Publications (1)
- DERIVEDSemenov D, Achkasov S, Bodunova N, Avdalyan A, Barinov A, Chegodar A, Chernikovskiy I, Chizhikov N, Danilov M, Demidova I, Dmitriev V, Erygin D, Fedyanin M, Galkin V, Ivanilova D, Kanner D, Karnaukhov N, Karpov O, Khatkov I, Kolesnikova D, Kotova E, Maynovskaia O, Penzin O, Pikunov D, Pulin A, Savelov N, Semenova A, Shatalov V, Shubin V, Sklyar I, Yudin O, Zakurdaev E, Pokataev I, Tsukanov A. Prevalence and clinicopathological correlates of MSI/dMMR in colorectal cancer: a prospective multicenter registry study from Russia. Front Oncol. 2026 Aug 18;16:1883562. doi: 10.3389/fonc.2026.1883562. eCollection 2026. PMID 42682457